approved and emerging treatment options for transplant-ineligible patients with high-risk mds
Published 1 year ago • 95 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
2:18
evolving treatment options in ndmm: transplant-eligible and transplant-ineligible patients
-
3:38
a new set of treatment options for low-risk mds
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
5:43
pre- and post-allohsct treatment in mds
-
3:10
how mutation screening impacts transplant decisions in mds
-
2:50
magrolimab azacitidine in untreated higher-risk mds
-
4:16
pre-mds states: identifying patients at risk and using modern tools to improve prognosis
-
2:16
current and future treatment approaches for hr-mds
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
2:48
validation of iwg 2023 criteria for response to treatment with hma in hr-mds
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:30
the prognostic value of patient-reported outcomes in mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:35
methods of optimizing transplantation in mds
-
1:18
update on immunotherapy in mds